Form 4: KalVista Pharmaceuticals Acquired by Chiesi Farmaceutici

Director Patrick Treanor reports the cancellation of stock options following the completion of KalVista Pharmaceuticals' acquisition by Chiesi Farmaceutici.

Summary

• KalVista Pharmaceuticals, Inc. (KALV) has been acquired by Chiesi Farmaceutici S.p.A. via a merger with Skyline Merger Sub, Inc.
• The acquisition was completed on June 11, 2026, with shareholders receiving $27.00 per share in cash.
• Reporting person Patrick Treanor disposed of 67,000 total stock options as part of the merger agreement.
• Options with exercise prices below the $27.00 merger consideration were converted into the right to receive a cash payment equal to the spread.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing confirming the completion of a previously announced acquisition.

Positives

• Successful completion of the merger transaction at a cash consideration of $27.00 per share.
• Full vesting and cash-out of in-the-money stock options for the reporting person.

Negatives

• Delisting of KalVista Pharmaceuticals as a publicly traded entity following the merger.
• Cancellation of out-of-the-money options for no consideration.

Risks

• No ongoing risks as the company is now a wholly owned subsidiary of Chiesi Farmaceutici.

Future Outlook

The company is now a wholly owned subsidiary of Chiesi Farmaceutici S.p.A.; no further public guidance or forward-looking statements are expected from the former independent entity.

Industry Context

StockSavvy.ai notes that this acquisition represents a consolidation trend in the biopharmaceutical sector, where larger global players like Chiesi Farmaceutici are acquiring specialized firms to bolster their rare disease or specialty drug pipelines.

Comparison to Industry Standards

• The $27.00 per share cash offer is a definitive exit event for shareholders.
• The treatment of stock options (cash-out for in-the-money, cancellation for out-of-the-money) is standard practice in pharmaceutical M&A transactions.

Stakeholder Impact

• Shareholders have received cash consideration for their equity holdings.
• The company has transitioned from a public entity to a private subsidiary.

Next Steps

• Finalization of integration into Chiesi Farmaceutici S.p.A.

Key Dates

Keywords

KalVista Pharmaceuticals, Merger, Acquisition, Chiesi Farmaceutici, Form 4, Insider Transaction